Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc

Expert Opinion on Therapeutic Patents · Published 2025-08-20 · DOI 10.1080/13543776.2025.2548925

Authors being retrieved — see the publisher record. https://doi.org/10.1080/13543776.2025.2548925

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage · Expert Opinion on Therapeutic Patents · 2026 · Cites or is cited by this article · Same journal
Sirtuin modulators: a review of patents from 2020 to 2024 · Expert Opinion on Therapeutic Patents · 2025 · Same journal
A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019–2024) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020–2025) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
PCSK9 inhibitors: an updated patent review 2024–2025 · Expert Opinion on Therapeutic Patents · 2026 · Same journal
Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience · Expert Opinion on Therapeutic Patents · 2025 · Same journal